By www.marketscagr.com
Global And United States Targeted Drug EGFR RTK Inhibitors For NSCLC Market Report & Forecast 2023-2028 Story
118
$ 4350
Targeted Drug EGFR RTK Inhibitors For NSCLC Report report is categorised based on following features:
1. Global Market Players
2. Geopolitical regions
3. Consumer Insights
4. Technological advancement
5. Historic and Future Analysis of the Market
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India